Breaking News Instant updates and real-time market news.

PEP

PepsiCo

$114.99

0.01 (0.01%)

, SODA

Acquired by PEP

$142.36

12.47 (9.60%)

12:08
08/20/18
08/20
12:08
08/20/18
12:08

Fly Intel: Wall Street's top stories at midday

Stocks opened higher across the board, but while the Dow moved higher, the Nasdaq gave up its gains. The averages remain mixed with the news flow light and the volume low, as is typical for end of summer trading. Oil prices are slightly higher after beginning the day in negative territory. ECONOMIC EVENTS: In the U.S., no economic reports of note were released. COMPANY NEWS: PepsiCo (PEP) announced a deal to buy SodaStream (SODA) for $144 per share in cash in a $3.2B transaction that likely represents the last big bet being placed by outgoing CEO Indra Nooyi. PepsiCo's "strong distribution capabilities, global reach, R&D, design and marketing expertise, combined with SodaStream's differentiated and unique product range will position SodaStream for further expansion and breakthrough innovation," the companies stated... JPMorgan analyst Ryan Brinkman lowered his price target on Tesla (TSLA) shares to $195 from $308 as he reverts back to valuing the shares on the basis of fundamentals alone. While the analyst acknowledged that Tesla does appear to be exploring a going private transaction, he now believes that such a process appears much less developed than he had earlier presumed, suggesting formal incorporation into his valuation analysis seems premature at this time. MAJOR MOVERS: Among the noteworthy gainers was China Biologic (CBPO), which jumped 11% after a consortium of investors proposed to acquire the company for $118 per share. Also higher was Nike (NKE), which gained 3% after Susquehanna analyst Sam Poser upgraded the stock to Positive from Neutral and Piper Jaffray analyst Erinn Murphy upgraded the stock to Overweight from Neutral. Among the notable losers was Lannett (LCI), which plunged over 58% after it reported preliminary Q4 results and said it will not renew its contract with Jerome Stevens Pharmaceuticals. Also lower was Infosys (INFY), which fell 3% after Morgan Stanley downgraded the stock to Equal Weight from Overweight following strong year-to-date outperformance. INDEXES: Near midday, the Dow was up 106.31, or 0.41%, to 25,775.63, the Nasdaq was down 1.64, or 0.02%, to 7,814.69, and the S&P 500 was up 6.87, or 0.24%, to 2,857.00.

PEP

PepsiCo

$114.99

0.01 (0.01%)

SODA

Acquired by PEP

$142.36

12.47 (9.60%)

TSLA

Tesla

$302.31

-3.02 (-0.99%)

CBPO

China Biologic

$102.02

9.96 (10.82%)

NKE

Nike

$82.20

2.47 (3.10%)

LCI

Lannett

$5.58

-7.925 (-58.70%)

INFY

Infosys

$20.40

-0.685 (-3.25%)

  • 20

    Aug

  • 28

    Aug

  • 12

    Sep

  • 02

    Oct

  • 29

    Oct

PEP PepsiCo
$114.99

0.01 (0.01%)

08/14/18
EVER
08/14/18
NO CHANGE
EVER
BodyArmor stake positive for Coca-Cola, negative for Pepsi, says Evercore
Evercore ISI analyst Robert Ottenstein views Coca-Cola's stake in BodyArmor as a "clear positive" for the company and a "clear negative" for both PepsiCo (PEP) and Keurig Dr Pepper (KDP). Pepsi's Gatorade product is most at risk with Coca-Cola taking a stake in BodyArmor, and Keurig Dr Pepper "losses distribution of the product and any path to ownership it might have enjoyed," Ottenstein tells investors in a research note.
07/16/18
RBCM
07/16/18
NO CHANGE
Target $75
RBCM
Outperform
Monster Beverage price hike to come November 1st, says RBC Capital
RBC Capital analyst Nik Modi says his industry sources have confirmed that Monster Beverage (MNST) intends to raise its prices by 4.0-5.5% on November 1st depending on the pack size, which would be in line with the management's indication of pricing review made at the June shareholder meeting. The analyst keeps his Outperform rating and $75 price target on Monster, adding that Coca Cola (KO), PepsiCo (PEP) and Keurig Dr Pepper (KDP) will also likely make pricing changes in response over the coming months.
07/23/18
JEFF
07/23/18
NO CHANGE
Target $107
JEFF
Hold
Jefferies sees risk of near-term downside in PepsiCo shares
Jefferies analyst Kevin Grundy sees potential near-term downside in shares of PepsiCo. Despite fundamental challenges and weak earnings quality, PepsiCo's "relative multiple remains elevated," Grundy tells investors in a research note. The analyst is "negatively biased" toward PepsiCo and reiterates a Hold rating on the shares with a $107 price target.
07/24/18
RHCO
07/24/18
NO CHANGE
Target $110
RHCO
Hold
PepsiCo price target raised to $110 from $105 at SunTrust
SunTrust analyst William Chappell raised his price target on PepsiCo to $110 to account for gains related to the impact of refranchising transactions, which he expects to support the company's high-single-digit EPS growth trend going forward. The analyst also keeps his Hold rating on PepsiCo as the stock is "fairly valued", with the company's Beverage business trading in line with peers and the Food business trading at the high end of its large-cap snack food peer range.
SODA Acquired by PEP
$142.36

12.47 (9.60%)

09/25/17
SUSQ
09/25/17
NO CHANGE
Target $90
SUSQ
Positive
SodaStream price target raised to $90 from $79 at Susquehanna
Susquehanna analyst Pablo Zuanic raised his price target on SodaStream to $90 from $79 after meetings with the company, during which it said it is adding about 1M households per year to its platform. He said those numbers could prove to be conservative given its plans to triple its penetration in Germany and a reinvigorated push in the U.S. He sees improved economics, including higher machine margins, lower customer acquisition costs, new plant efficiencies, and improved EBIT. Zuanic reiterated his Positive rating on SodaStream shares.
04/03/18
RILY
04/03/18
INITIATION
Target $110
RILY
Buy
SodaStream initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Jeff Van Sinderen started SodaStream with a Buy rating and $110 price target. The analyst sees growth opportunities both in the U.S. and abroad.
04/04/18
04/04/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AT&T (T) initiated with a Buy at Spin-Off Research. 2. Spotify (SPOT) initiated with a Hold at Gabelli. 3. Wix.com (WIX) initiated with an Outperform at William Blair. 4. SodaStream (SODA) initiated with a Buy at B. Riley FBR. 5. Booking Holdings (BKNG) initiated with an Outperform at Wedbush while Expedia (EXPE), TripAdvisor (TRIP), and Trivago (TRVG) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TSLA Tesla
$302.31

-3.02 (-0.99%)

08/20/18
SBSH
08/20/18
NO CHANGE
SBSH
Neutral
Tesla may be wise to try equity capital raise sooner than later, says Citi
Citi analyst Itay Michaeli said he doesn't think Tesla has necessarily entered a "spiral" of declining confidence that could put its financial position into distress, but he thinks it would be wise for the company to at least try to raise significant new equity capital sooner rather than later if a go-private deal is looking less likely. If management doesn't see such a capital raise as necessary, he believes a "mid-quarter" update of some sort would be helpful given the heightened focus on its balance sheet that recent events have created. The analyst, who keeps a Neutral rating on Tesla shares, thinks a call on the stock requires a "high degree of conviction in either direction" given the potential for extreme outcomes.
08/20/18
08/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN CUTS TESLA PRICE TARGET: JPMorgan analyst Ryan Brinkman reduced his price target on Underweight-rated Tesla (TSLA) back to $195 from $308, telling investors that he is reverting back to valuing shares on the basis of fundamentals alone. While Brinkman said that Tesla "does appear to be exploring a going private transaction," he believes that such a process appears "much less developed" than he had earlier presumed and is "more along the lines of high level intention," suggesting formal incorporation into his valuation analysis "seems premature." NIKE UPGRADED AT TWO FIRMS: Piper Jaffray analyst Erinn Murphy upgraded Nike (NKE) to Overweight from Neutral and raised her price target for shares to $93 from $72, telling investors she believes the risk profile of owning Nike shares has "considerably diminished" and sees Nike moving from downward EPS revisions to upward revisions supported by a stabilizing North America landscape, strong margin and sales drivers and improving brand momentum. Susquehanna analyst Sam Poser upgraded Nike to Positive from Neutral. The analyst cited its market share gains, and gains within the family footwear channel specifically, due to improved product offerings and product flow. He raised his price target to $93 from $78 on Nike shares. QUALCOMM UPGRADED TO BUY: Rosenblatt analyst Jun Zhang upgraded Qualcomm (QCOM) to Buy from Neutral and increased its price target to $70 from $57 citing benefits from 5G smartphone growth over the next few years, Zhang said Qualcomm's 5G RF module is better positioned than their 4G product and should continue to gain share in the high-end market due to MediaTek's smartphone chipset roadmap losing traction. BLOOM ENERGY INITIATIONS ALL OVER MAP: Morgan Stanley analyst Stephen Byrd started Bloom Energy (BE) with an Overweight rating and $30 price target, calling the company "a true disruptor" that is revolutionizing on-site power with its natural gas fuel cell systems. Credit Suisse analyst Michael Weinstein started Bloom Energy with a Neutral rating and $24 price target. After a nearly 80% jump off the $15 IPO, the analyst believes that current pricing captures a fair balance between the risk of executing continued cost reductions and the possible upside from accelerating sales growth once the investment tax credit sunsets in 2023. BofA/Merrill analyst Julien Dumouln-Smith initiated Bloom Energy with an Underperform and $19 price target citing high expectations and execution risks over costs and deployment.
08/20/18
JPMS
08/20/18
NO CHANGE
Target $195
JPMS
Tesla price target cut to $195 from $308 at JPMorgan
JPMorgan analyst Ryan Brinkman reduced his price target on Underweight-rated Tesla back to $195 from $308, telling investors that he is reverting back to valuing shares on the basis of fundamentals alone. Brinkman says that his interpretation of events leads him to believe that funding was not secured for a going private transaction, nor was there any formal proposal. While Brinkman says that Tesla "does appear to be exploring a going private transaction," he believes that such a process appears "much less developed" than he had earlier presumed and is "more along the lines of high level intention," suggesting formal incorporation into his valuation analysis "seems premature."
08/16/18
EVER
08/16/18
NO CHANGE
Target $301
EVER
In Line
After visiting Tesla's Freemont facility, Evercore ISI says Model 3 'on track'
Evercore ISI analyst George Galliers said he is a bit more positive on Tesla following his trip to the company's Freemont facility, stating that Tesla "seems well on the way" to achieving steady production of 5,000 to 6,000 Model 3 units per week and that reaching 7,000 to 8,000 units per week seems "well within reach." Following the trip, he said the Model 3 looks to be "on track" and while he continues to forecast second half Model 3 production of 123,000 units, Galliers now believes his estimate could be 4%-7% too low. He maintains an In Line rating on Tesla shares with a $301 price target.
CBPO China Biologic
$102.02

9.96 (10.82%)

08/06/18
FBCO
08/06/18
DOWNGRADE
FBCO
Neutral
China Biologic downgraded to Neutral from Outperform at Credit Suisse
03/02/18
DBAB
03/02/18
NO CHANGE
Target $105
DBAB
Buy
China Biologic shares 'cheap' at current levels, says Deutsche Bank
Deutsche Bank analyst Jack Hu says that while near-term pressure on shares of China Biologic Products, the stock is "cheap" at current levels. The analyst lowered his price target for the shares to $105 and $116 and keeps a Buy rating on China Biologic.
05/14/18
JEFF
05/14/18
DOWNGRADE
Target $83
JEFF
Hold
China Biologic downgraded to Hold from Buy at Jefferies
As previously reported, Jefferies analyst Johnny Kin Man Wong downgraded China Biologic Products to Hold from Buy and cut his price target on shares to $83 from $97 citing a lack of visibility ahead. In a research note to investors, the analyst said healthcare reforms are likely to impact the company more harshly than originally expected as hospitals continue to hold back from ordering despite what he feels is healthy end demand.
05/14/18
JEFF
05/14/18
DOWNGRADE
JEFF
Hold
China Biologic downgraded to Hold from Buy at Jefferies
NKE Nike
$82.20

2.47 (3.10%)

08/20/18
SUSQ
08/20/18
UPGRADE
Target $93
SUSQ
Positive
Nike upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded Nike to Positive from Neutral. The analyst cited its market share gains and gains within the family footwear channel. The gains are due to improved product offerings and product flow, putting the company on pace to meet its 2023 $50B revenue target, said Poser. He raised his price target to $93 from $78 on Nike shares.
08/20/18
SUSQ
08/20/18
UPGRADE
SUSQ
Positive
Nike upgraded to Positive from Neutral at Susquehanna
08/20/18
08/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Positive from Neutral at Susquehanna and to Overweight from Neutral at Piper Jaffray. 2. Qualcomm (QCOM) upgraded to Buy from Neutral at Rosenblatt with analyst Jun Zhang citing benefits from 5G smartphone growth over the next few years. 3. Flir Systems (FLIR) upgraded to Outperform from Market Perform at William Blair with analyst Louie DiPalma he believes, in the near-term, Flir's enhanced automation and software capabilities are rendering its sensors more powerful and driving adoption. Additionally, DiPalma believes thermal sensors will be common in autonomous vehicles over the longer term, which could be a major source of long-term upside. 4. RBS (RBS) upgraded to Buy from Neutral at Citi. 5. Terex (TEX) upgraded to Neutral from Underperform at Baird with analyst Mig Dobre citing its recent pullback and multiple compression as well as its upcoming investors day. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LCI Lannett
$5.58

-7.925 (-58.70%)

08/20/18
ROTH
08/20/18
DOWNGRADE
Target $8
ROTH
Neutral
Lannett downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Lannett Company to Neutral from Buy and reduced his price target to $8 from $23 after the company announced that Jerome Stevens Pharmaceuticals will not renew its contract, impacting key revenue streams for the company, including levothyroxine, digoxin and butalbital. Henry tells investors in a research note that valuation is "interesting," but the risk profile remains "high" given its debt load.
06/18/18
DBAB
06/18/18
NO CHANGE
DBAB
Lannett falls after Deutsche Bank addresses 'elephant in the room'
Shares of Lannett after falling after Deutsche Bank analyst Gregg Gilbert told investors to brace for "significant volatility" on the upcoming levothyroxine outcome. The "elephant in the room" is that depending on ongoing negotiations with Lannett's partner Jerome Stevens Pharmaceuticals, the company's largest product levothyroxine, which represented 34% of sales in fiscal 2018, could go away in March 2019, Gilbert wrote earlier in a research note. The product, however, could remain part of the Lannett portfolio for years to come if the partnership term is extended, the analyst added. Gilbert predicts the stock "could crumble" if the agreement is not extended. On the flip side, the shares could spike as "shorts are squeezed" if Lannett were to reach a new deal with Jerome Stevens, Gilbert says. He expects to see this situation "come to a head" over the next two months. Lannett's new CEO Tim Crew has a sense of urgency to get this done, Gilbert believes. The analyst sees the most likely outcome as an extension to the agreement, "perhaps at some additional cost" to Lannett. Such an outcome "could help the shares move higher in the short term, and set the stage for interesting strategic options longer term," Gilbert explains. He keeps a Hold rating on Lannett. The stock in morning trading is down 6%, or $1.00, to $14.90.
01/24/18
GSCO
01/24/18
INITIATION
Target $21
GSCO
Neutral
Lannett initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated Lannett with a Neutral and $21 price target.
08/20/18
ROTH
08/20/18
DOWNGRADE
ROTH
Neutral
Lannett downgraded to Neutral from Buy at Roth Capital
INFY Infosys
$20.40

-0.685 (-3.25%)

08/20/18
08/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Constellation Brands (STZ, STZ.B) downgraded to Negative from Neutral at Susquehanna with analyst Pablo Zuanic citing valuation. 2. Infosys (INFY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Parag Gupta citing a belief that concerns around senior management exits will remain an overhang on the stock. 3. YogaWorks (YOGA) downgraded to Market Perform from Outperform at Cowen with analyst Oliver Chen saying he sees risk to visitation and revenue trends with the company's medium-term priorities of pulling back on promotions and marketing. 4. News Corp. (NWSA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Andrew McLeod saying its Australian payTV unit, Foxtel, will launch a new OTT sports service by the end of 2018, which presents the "obvious risk" that its existing subscriber base and high ARPU will come under pressure. 5. Park Hotels & Resorts (PK) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/20/18
08/20/18
DOWNGRADE

Equal Weight
Infosys downgraded to Equal Weight following outperformance at Morgan Stanley
As previously reported, Morgan Stanley analyst Parag Gupta downgraded Infosys to Equal Weight from Overweight following strong year-to-date outperformance and citing a belief that concerns around senior management exits will remain an overhang on the stock. With the company in the first year of a three-year transformation journey, Gupta sees limited upside risks to FY19 revenue growth and margins, the analyst tells investors. Gupta has a Rs1,450 price target on Infosys shares.
08/20/18
MSCO
08/20/18
DOWNGRADE
MSCO
Equal Weight
Infosys downgraded to Equal Weight from Overweight at Morgan Stanley
07/12/18
DBAB
07/12/18
INITIATION
DBAB
Buy
Infosys initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Srinivas Roa started Infosys with a Buy rating and INR 1,495 price target. The analyst sees currency tailwinds helping the company's financials in fiscal 2019.

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.